Summary & Overview
HCPCS J2783: Injection, rasburicase, 0.5 mg
HCPCS Level II code J2783 denotes an injection of rasburicase, 0.5 mg, an injectable biologic used to rapidly lower serum uric acid in patients at risk for tumor lysis syndrome. The code is relevant across acute and ambulatory infusion settings where oncology-supportive treatments are administered and has national significance due to the high-cost nature of biologics and the clinical need for timely management of metabolic complications in oncology and hematology care. Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise explanation of the clinical purpose of J2783, typical sites of service, and the service type. The publication provides reimbursement benchmarks, common billing and modifier considerations, and context on utilization patterns for rasburicase in supportive oncology care. Policy and payer coverage trends relevant to high-cost injectable therapies are summarized to inform coding, billing, and administrative workflows. Data not provided in the input are noted where applicable.
Billing Code Overview
HCPCS Level II code J2783 describes an injection of rasburicase, 0.5 mg. This medication is an enzymatic urate oxidase used to lower serum uric acid levels in patients at risk for tumor lysis syndrome or other conditions with rapid cell turnover. The service type is injectable biologic therapy administered parenterally. The typical site of service is an inpatient hospital setting, outpatient infusion center, or clinic where injectable oncology-supportive care is provided.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric oncology patient at risk for tumor lysis syndrome (TLS) following initiation of cytotoxic chemotherapy or targeted therapy. The patient presents to an outpatient oncology infusion center, hospital inpatient ward, or emergency department for parenteral therapy. The oncology team orders J2783 (rasburicase, 0.5 mg) to rapidly lower elevated serum uric acid when hyperuricemia is observed or anticipated (for example, in acute leukemia or high‑tumor‑burden lymphoma). Prior to administration, nursing verifies weight-based dosing, obtains baseline labs (serum uric acid, creatinine, electrolytes), screens for G6PD deficiency in at‑risk populations when clinically indicated, and prepares the appropriate rasburicase dose. The medication is administered intravenously per facility protocol; monitoring includes repeat serum uric acid and observation for infusion reactions or hemolysis. Documentation includes indication (e.g., prevention or treatment of TLS), dose/units billed as J2783 per 0.5 mg increment, site of service (outpatient infusion center, inpatient hospital unit, or emergency department), and any applicable modifiers (for example, modifier JW for discarded drug when partial vial wastage occurs).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |